Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: A French perspective

International Journal of Clinical Practice

Volumn 61, Issue 11, 2007, Pages 1805-1811

  Roze, S ^a   Ferrieres J ^b   Bruckert, E ^c   Van Ganse, E ^d   Chapman, M J ^c   Liens, D ^e   Renaudin, C ^f  

^a IQVIA   (United States)

^b CHU RANGUEIL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

^e Medical Affairs   (France)

^f Pricing and Economics   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG RELEASE; FEMALE; FRANCE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT OUTCOME; WESTERN EUROPE;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; NIACIN; TREATMENT OUTCOME;

EID: 35348852547     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01546..x     Document Type: Article

References (30)

1. Petersen S, Peto V, Rayner M et al. European Cardiovascular Disease Statistics. London : British Heart Foundation, 2005.
2. Leal J, Luengo-Fernandez R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006 27 : 1610 9.
3. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
4. International Atherosclerosis Society. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease, 2003. http://www.athero.org (accessed September 2006).
5. De Backer G, Ambrosioni E, Borch-Johnsen K et al. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003 24 : 1601 10.
6. AFSSAPS. Prise en charge thérapeutique du patient dyslipidémique. March 2005. http://afssaps.sante.fr/pdf/5/rbp/dysreco.pdf (accessed September 2006).
7. Baigent C, Keech A, Kearney PM et al. Cholesterol treatment trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
8. Pedersen TR, Assmann G, Bassand J-P et al., on behalf of the European Expert Panel. Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diab Vasc Dis Res 2006 3 (Suppl. 2 S1 S12.
9. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005 21 : 1927 34.
10. Bruckert E. Epidemiology of low HDL-cholesterol: results of studies and surveys. Eur Heart J 2006 8 (Suppl. F F17 22.
11. Hansel B, Kontush A, Giral P et al. One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study. Curr Med Res Opin 2006 22 : 1149 60.
12. Ferrieres J, Ruidavets JB, Perret B et al. Prevalence of dyslipidaemias in a representative sample of the French population. Arch Mal Coeur Vaiss 2005 98 : 127 32 French PL, Keating GM. Prolonged-release nicotinic acid. A review of its use in the treatment of dyslipidaemia. Drugs 2005 65 : 2719 40.
13. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998 47 : 1097 104.
14. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the Advicor Versus Other Cholesterol modulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol 2003 91 : 667 72.
15. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
16. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006 22 : 2243 50.
17. Dictionnaire VIDAL. Paris : Editions du Vidal, 2005.
18. Roze S, Liens D, Palmer A et al. A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease. Curr Med Res Opin 2006 22 : 2549 56.
19. Fagnani F, Souchet T, Labed D. Incidence, management and cost of cardio-vascular and renal complications in French type 2 diabetic patients in2001. Value Health 2003 6 : 320 abstract PCV 36).
20. Montagne O, Chaix C, Harf A et al. Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. Pharmacoeconomics 2000 17 : 603 9.
21. Levy P, Lechat P, Leizorovicz A, Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998 12 : 301 5.
22. Mullins CD, Sikirica M, Seneviratne V et al. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004 22 : 1001 14.
23. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000 23 : 390 404.
24. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge Value Health 2004 7 : 518 28.
25. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: a comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998 137 (Suppl. S111 6.
26. Roze S, Wierzbicki AS, Liens D, Renaudin C. Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol: a UK-based economic evaluation. Br J Cardiol 2006 13 : 411 8.
27. Farnier M, Garnier P, Yau C et al. Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: the ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey. Int J Clin Pract 2006 60 : 1166 71.
28. Cook JR, Yin D, Alemao E et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004 22 (Suppl. 3 49 61.
29. Kohli M, Attard C, Lam A et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics 2006 24 : 815 30.
30. Kos Pharmaceuticals Inc. Niaspan (niacin extended-release tablets): US prescribing information [online]. http://www.niaspan.com.